Search results
Added:
2 years ago
Find out what your colleagues are talking about, tune in to our Optimal Management of Cardiac Implantable Electronic Device Infections podcast! Renowned industry experts explore what CIED infections mean for you and your patients. Find out why antibiotics alone do not work and what you can do. Plus, watch our unmissable patients stories episode.
Click here to watch the video versions
View more
Added:
3 weeks ago
Added:
6 months ago
Added:
3 days ago
Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview Questions:Can you provide an overview…
View more
Added:
8 months ago
Added:
3 weeks ago
HFSA 25 - CCM-D was associated with successful defibrillation and symptom improvement in patients with HFrEF at 6 months in the INTEGRA-D Trial.Dr Nir Uriel (NewYork-Presbyterian, Columbia University Irving Medical Center, US) joins us to discuss findings from the Integra-D trial, evaluating a novel implantable device that provides both cardiac contractility modulation and defibrillation…
View more
Added:
3 months ago
Added:
2 months ago
Navigate the diagnostic complexities of cardiac amyloidosis through expert multimodality imaging techniques with Dr Vasvi Singh.This comprehensive presentation, part of the Cardiomyopathies track, addresses the critical role of advanced imaging in diagnosing cardiac amyloidosis. Dr Singh explores the nuanced differences between SPECT and SPECT-CT imaging capabilities, providing practical insights…
View more
Added:
2 months ago
Discover the rapidly evolving therapeutic options transforming outcomes for cardiac amyloidosis patients with Dr Sarah Cuddy.This comprehensive presentation, part of the Cardiomyopathies track, explores the dramatic advances in both TTR and AL amyloidosis treatment over the past decade. Dr Cuddy examines how modern therapeutic approaches have fundamentally shifted survival curves, particularly…
View more
Added:
2 months ago
ESC Congress 2025 - Digitoxin reduced the risk of all-cause mortality and hospitalisation in patients with worsening heart failure.Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Udo Bavendiek to explore the DIGIT-HF trial, investigating whether digitoxin can improve outcomes in patients with advanced chronic heart failure and reduced ejection fraction.This landmark study…
View more